Emyria (ASX:EMD) to initiate psychedelic-assisted therapy program for PTSD

Summary

  • ASX-listed drug development and clinical services company Emyria Limited has launched a psychedelic-assisted therapy program with Mind Medicine Australia.
  • The Company disclosed the EMDMA-001 program would address key challenges in MDMA-assisted therapy.
  • Emyria also plans to explore other MDMA and psilocybin-assisted therapy programs to treat depression and substance abuse.

An innovative drug development and clinical services company Emyria Limited (ASX:EMD), announced the launch of a psychedelic-assisted therapy program, EMDMA-001, developed with partner Mind Medicine Australia.

ASX 200 is up today, gaining 0.68% to reach 7115.70 (at AEST 11:22 AM). The top-performing stocks in this index are Nearmap Ltd (ASX:NEA), Janus Henderson Group Plc (ASX:JHG), and QBE Insurance Group Limited (ASX:QBE), up 13.59%, 4.47%, and 3.19%, respectively.

ALSO READ: ASX 200 on Wednesday: Top 5 things to watch out

Emyria to initiate psychedelic-assisted therapy program

The EMDMA-001 program will target Post Traumatic Stress Disorder (PTSD). As a first step and pending ethics approval for the program, EMD will sponsor a major, independently monitored clinical trial under the EMDMA-001 program.  The study will target treatment-resistant PTSD with evidence-based MDMA-assisted therapy.

EMDMA-001 has been modelled on a significant Phase 3 clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).

Source: Copyright © 2021 Kalkine Media Pty Ltd

A major priority of this first program is to support the evaluation of the long-term safety, efficacy, and cost benefits of MDMA-assisted psychotherapy. Such evidence is required for delivering psychedelic-assisted care in a safe, standardised, and scalable manner.

Other than EMDMA-001, the Company also intends to explore other MDMA- and psilocybin-assisted therapy programs for the treatment of depression and substance abuse.

It is noteworthy to mention that psilocybin-assisted therapy for the treatment of resistant depression and major depressive disorder and MDMA-assisted therapy for PTSD has been granted Breakthrough Therapy status by the US Food and Drug Administration (FDA).

Dr Michael Winlo, Managing Director of Emyria, commented-

EMDMA-001 program to focus on major challenges in MDMA

The Company also disclosed that the EMDMA-001 program would address major challenges encountered in MDMA-assisted therapy. Furthermore, novel research and specialised training are required for the method of administration of MDMA-assisted therapy.

In general, MDMA-assisted therapy involves three general stages:

Source: Copyright © 2021 Kalkine Media Pty Ltd (Source: EMD Announcement)

Some patients may also require repeating the cycles mentioned above, and a clinical service should be prepared for supporting patients through the entire experience and beyond.

Outlook: the way forward

  • With Mind Medicine Australia, EMD is confident that it is uniquely positioned to deliver the requisite clinical services while also generating strong and ethically sourced clinical evidence to advance the field.
  • The first cohort of trained therapists will graduate this month from Mind Medicine Australia’s therapist training course. EMD has already equipped a fit-for-purpose facility.
  • The Company is finalising a protocol that is anticipated to be submitted to ethics shortly with all the required regulatory measures carefully observed.

Furthermore, Emyria will provide further updates as the program advances.

Stock Information: At AEST 11:28 AM, EMD shares were trading at AU$0.260, in line with the previous close.

ALSO READ: Three ASX penny stocks in the healthcare space – OCC, ATX and EMD


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK